

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:23:28 ON 08 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 AUG 2006 HIGHEST RN 899508-12-4
DICTIONARY FILE UPDATES: 7 AUG 2006 HIGHEST RN 899508-12-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10659091core.str



chain nodes :
 6 7 8 9 10 11 12 13 14 15 16 18 20 21 22 24 25 27 28
 ring nodes :
 1 2 3 4 5
 chain bonds :
 3-6 4-11 5-15 5-16 6-7 6-28 7-21 8-9 8-22 9-10 10-24 11-12 12-13 13-14
 13-18 14-27 15-20 21-22 24-25
 ring bonds :
 1-2 1-5 2-3 3-4 4-5
 exact/norm bonds :
 1-2 1-5 2-3 3-4 4-5 5-15 10-24 12-13 13-14 13-18 14-27 15-20 24-25
 exact bonds :
 3-6 4-11 5-16 6-7 6-28 7-21 8-9 8-22 9-10 11-12 21-22

G1:O,S

G2:H,Ak

G3:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:CLASS
 20:CLASS 21:CLASS 22:CLASS 24:CLASS 25:CLASS 27:CLASS 28:CLASS

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 12:23:51 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 4 TO 200


PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S

G2 H,Ak

G3 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

FULL SEARCH INITIATED 12:24:02 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 50 TO ITERATE

100.0% PROCESSED 50 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=> log hold

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

167.38 167.59

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:24:45 ON 08 AUG 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'REGISTRY' AT 12:26:17 ON 08 AUG 2006

FILE 'REGISTRY' ENTERED AT 12:26:17 ON 08 AUG 2006

COPYRIGHT (C) 2006 American Chemical Society (ACS)

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION



FULL ESTIMATED COST

167.38

167.59

=>

Uploading C:\Program Files\Stnexp\Queries\10659091core2.str



chain nodes :

6 7 8 9 10 11 12 13 14 15 16 18 20 21 22 24 25 27 28 29 30 31
32 33 34 35

ring nodes :

1 2 3 4 5

chain bonds :

1-28 1-29 3-6 3-33 4-11 4-30 5-15 5-16 6-7 6-34 6-35 7-21 8-9 8-22
 9-10 10-24 11-12 11-31 11-32 12-13 13-14 13-18 14-27 15-20 21-22 24-25
 ring bonds :
 1-2 1-5 2-3 3-4 4-5
 exact/norm bonds :
 1-2 1-5 2-3 3-4 4-5 5-15 10-24 11-12 12-13 13-14 13-18 14-27 15-20
 24-25
 exact bonds :
 1-28 1-29 3-6 3-33 4-11 4-30 5-16 6-7 6-34 6-35 7-21 8-9 8-22 9-10
 11-31 11-32 21-22

G1:O,S

G2:H,Ak

G3:O,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:CLASS
 20:CLASS 21:CLASS 22:CLASS 24:CLASS 25:CLASS 27:CLASS 28:CLASS 29:CLASS
 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR



G1 O,S

G2 H,Ak

G3 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l4

SAMPLE SEARCH INITIATED 12:26:44 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS

SEARCH TIME: 00.00.01

1 ANSWERS


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 4 TO 200
 PROJECTED ANSWERS: 1 TO 80

L5 1 SEA SSS SAM L4

=> d l5 scan

L5 1 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 5-Heptenoic acid, 7-[(1R,2S,3R)-3-hydroxy-5-oxo-2-[[[(2-phenylethyl)amino]carbonyl]oxy]methyl]cyclopentyl]-, (5Z)- (9CI)
 MF C22 H29 N O6

Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l4 sss full
 FULL SEARCH INITIATED 12:27:06 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 50 TO ITERATE


100.0% PROCESSED 50 ITERATIONS 25 ANSWERS
 SEARCH TIME: 00.00.01

L6 25 SEA SSS FUL L4

=> d l6 scan

L6 25 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 5-Heptenoic acid, 7-[(1R,2S,3R,5S)-3,5-dihydroxy-2-[[[(phenylamino)carbonyl]oxy]methyl]cyclopentyl]-, methyl ester, (5Z)- (9CI)
 MF C21 H29 N O6

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L6 25 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 5-Heptenoic acid, 7-[(1R,2S,3R,5S)-3,5-dihydroxy-2-
 [[[phenylamino]carbonyl]oxy]methyl]cyclopentyl]-, (5Z)- (9CI)
 MF C20 H27 N O6


Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 25 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 5-Heptenoic acid, 7-[(1R,2S,3R,5S)-3,5-dihydroxy-2-
 [[[(phenylmethyl)amino]carbonyl]oxy]methyl]cyclopentyl]-, (5Z)- (9CI)
 MF C21 H29 N O6


Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 25 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 5-Heptenoic acid, 7-[(1R,2S,3R,5S)-2-[[[(butylamino)carbonyl]oxy]methyl]-
 3,5-dihydroxycyclopentyl]-, methyl ester, (5Z)- (9CI)
 MF C19 H33 N O6


Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 25 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 5-Heptenoic acid, 7-[(1R,2S,3R,5S)-3,5-dihydroxy-2-
 [[[(phenylmethyl)amino]thioxomethoxy]methyl]cyclopentyl]-, (5Z)- (9CI)
 MF C21 H29 N O5 S


Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 25 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Heptenoic acid, 7-[(1R,2S,3R)-2-[[[butylamino)thioxomethoxy)methyl]-3-
hydroxy-5-oxocyclopentyl]-, (5Z)- (9CI)
MF C18 H29 N O5 S

Absolute stereochemistry.
Double bond geometry as shown.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\Stnexp\Queries\10659091ketone.str



```

chain nodes :
6  7  8  9 10 11 12 13 14 15 16 18 20 21 22 24 25 27 28 29 30 31
32 33 34 35 36
ring nodes :
1  2  3  4  5
chain bonds :
1-28 1-29 2-36 3-6 3-33 4-11 4-30 5-15 5-16 6-7 6-34 6-35 7-21 8-9
8-22 9-10 10-24 11-12 11-31 11-32 12-13 13-14 13-18 14-27 15-20 21-22
24-25
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 2-36 3-4 4-5 5-15 10-24 11-12 12-13 13-14 13-18 14-27
15-20 24-25
exact bonds :
1-28 1-29 3-6 3-33 4-11 4-30 5-16 6-7 6-34 6-35 7-21 8-9 8-22 9-10
11-31 11-32 21-22

```

G1:O,S

G2:H,Ak

G3:O,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:CLASS
20:CLASS 21:CLASS 22:CLASS 24:CLASS 25:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS

L7 STRUCTURE UPLOADED

=> d 17

L7 HAS NO ANSWERS

L7 STR



G1 O,S

G2 H,Ak

G3 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s 17

SAMPLE SEARCH INITIATED 12:28:47 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 3 TO 163

PROJECTED ANSWERS: 1 TO 80

L8 1 SEA SSS SAM L7


=> d 18 scan

L8 1 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 5-Heptenoic acid, 7-[(1R,2S,3R)-3-hydroxy-5-oxo-2-[[[(2-phenylethyl)amino]carbonyl]oxy]methyl]cyclopentyl]-, (5Z)- (9CI)

MF C22 H29 N O6

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s 17 sss full

FULL SEARCH INITIATED 12:28:58 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 38 TO ITERATE

100.0% PROCESSED 38 ITERATIONS

6 ANSWERS

SEARCH TIME: 00.00.01

L9 6 SEA SSS FUL L7

=> d 19 scan


L9 6 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 5-Heptenoic acid, 7-[(1R,2S,3R)-2-[[butylamino]thioxomethoxy]methyl]-3-hydroxy-5-oxocyclopentyl]-, methyl ester, (5Z)- (9CI)

MF C19 H31 N O5 S

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3


L9 6 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 5-Heptenoic acid, 7-[(1R,2S,3R)-2-[[butylamino]thioxomethoxy]methyl]-3-hydroxy-5-oxocyclopentyl]-, (5Z)- (9CI)

MF C18 H29 N O5 S

Absolute stereochemistry.


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 6 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 5-Heptenoic acid, 7-[(1R,2S,3R)-2-[[[(butylamino)carbonyl]oxy]methyl]-3-hydroxy-5-oxocyclopentyl]-, methyl ester, (5Z)- (9CI)
 MF C19 H31 N O6


Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 6 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 5-Heptenoic acid, 7-[(1R,2S,3R)-2-[[[(butylamino)carbonyl]oxy]methyl]-3-hydroxy-5-oxocyclopentyl]-, (5Z)- (9CI)
 MF C18 H29 N O6

Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

503.02

503.23

FILE 'CAPLUS' ENTERED AT 12:29:55 ON 08 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Aug 2006 VOL 145 ISS 7

FILE LAST UPDATED: 7 Aug 2006 (20060807/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 19

L10 1 L9

=> d 110

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:220145 CAPLUS

DN 142:297917

TI Preparation of 2-(thiocarbamoyloxy)- and 2-(carbamoyloxy)cyclopentane-1-heptan(en)ioic acid compounds for treating ocular hypertension

IN Old, David W.; Burk, Robert M.

PA Allergan, Inc., USA

SO U.S. Pat. Appl. Publ., 12 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005054689	A1	20050310	US 2003-659091	20030909
	AU 2004272524	A1	20050324	AU 2004-272524	20040818
	CA 2537794	AA	20050324	CA 2004-2537794	20040818
	WO 2005026109	A1	20050324	WO 2004-US27001	20040818
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1663961	A1	20060607	EP 2004-781645	20040818
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	US 2003-659091	A	20030909		
	WO 2004-US27001	W	20040818		
OS	CASREACT 142:297917; MARPAT 142:297917				

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

1.60

504.83

FILE 'REGISTRY' ENTERED AT 12:30:30 ON 08 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 AUG 2006 HIGHEST RN 899508-12-4

DICTIONARY FILE UPDATES: 7 AUG 2006 HIGHEST RN 899508-12-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10659091halogen.str



chain nodes :
 6 7 8 9 10 11 12 13 14 15 16 18 20 21 22 24 25 27 28 29 30 31
 32 33 34 35 36 37
 ring nodes :
 1 2 3 4 5
 chain bonds :
 1-28 1-29 2-36 3-6 3-33 4-11 4-30 5-15 5-16 6-7 6-34 6-35 7-21 8-9
 8-22 9-10 10-24 11-12 11-31 11-32 12-13 13-14 13-18 14-27 15-20 21-22
 24-25 36-37
 ring bonds :
 1-2 1-5 2-3 3-4 4-5
 exact/norm bonds :
 1-2 1-5 2-3 3-4 4-5 5-15 10-24 11-12 12-13 13-14 13-18 14-27 15-20
 24-25
 exact bonds :
 1-28 1-29 2-36 3-6 3-33 4-11 4-30 5-16 6-7 6-34 6-35 7-21 8-9 8-22
 9-10 11-31 11-32 21-22 36-37

G1:O,S

G2:H,Ak

G3:O,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:CLASS
20:CLASS 21:CLASS 22:CLASS 24:CLASS 25:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS

L11 STRUCTURE UPLOADED

=> d l11

L11 HAS NO ANSWERS

L11 STR



G1 O,S

G2 H,Ak

G3 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l11

SAMPLE SEARCH INITIATED 12:31:39 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 1 TO 80

PROJECTED ANSWERS: 0 TO 0

L12 0 SEA SSS SAM L11

=> s l11 sss full

FULL SEARCH INITIATED 12:31:47 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L13 0 SEA SSS FUL L11

=> d his

(FILE 'HOME' ENTERED AT 12:23:15 ON 08 AUG 2006)

FILE 'REGISTRY' ENTERED AT 12:23:28 ON 08 AUG 2006

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 SSS FULL
L4 STRUCTURE UPLOADED
L5 1 S L4
L6 25 S L4 SSS FULL
L7 STRUCTURE UPLOADED
L8 1 S L7
L9 6 S L7 SSS FULL

FILE 'CAPLUS' ENTERED AT 12:29:55 ON 08 AUG 2006

L10 1 S L9

FILE 'REGISTRY' ENTERED AT 12:30:30 ON 08 AUG 2006

L11 STRUCTURE UPLOADED
L12 0 S L11
L13 0 S L11 SSS FULL

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

167.38

672.21

STN INTERNATIONAL LOGOFF AT 12:31:54 ON 08 AUG 2006

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 AUG 2006 HIGHEST RN 899508-12-4
DICTIONARY FILE UPDATES: 7 AUG 2006 HIGHEST RN 899508-12-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10659091ketone2.str

L1 STRUCTURE UPLOADED

=> ld l1


LD IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S

G2 H,Ak

G3 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:07:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 6 TO ITERATE

100.0% PROCESSED 6 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 6 TO 266
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 13:07:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 60 TO ITERATE


100.0% PROCESSED 60 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L3 2 SEA SSS FUL L1

=> d l3 scan

L3 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Heptenoic acid, 7-[(1R,2S,3R,5R)-2-[[[(butylamino)carbonyl]oxy]methyl]-5-chloro-3-hydroxycyclopentyl]-, (5Z)- (9CI)
MF C18 H30 Cl N O5

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Heptenoic acid, 7-[(1R,2S,3R,5R)-2-[[[(butylamino)carbonyl]oxy]methyl]-5-chloro-3-hydroxycyclopentyl]-, methyl ester, (5Z)- (9CI)
MF C19 H32 Cl N O5

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 13:07:40 ON 08 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Aug 2006 VOL 145 ISS 7

FILE LAST UPDATED: 7 Aug 2006 (20060807/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 1 L3

=> d 13



YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

=> d 14 ti abs bib

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of 2-(thiocarbamoyloxy)- and 2-(carbamoyloxy)cyclopentane-1-heptan(en)oic acid compounds for treating ocular hypertension

GI



AB A method of treating ocular hypertension (glaucoma) comprises administering to a mammal having ocular hypertension a therapeutically effective amount of a compound represented by formula (I) [wherein a wavy segments indicate either the α or β configuration; the dashed bond represents a double bond or a single bond; U = :O, α - or β -halo; Z = O, S; Ar = (un)substituted C4-10 aryl or heteroaryl; n = 0-4; x, y = 0, 1; provided that when x is 1, yr is 0 and when x is 0, yr is 1; R1 = H, (un)substituted C \leq 6 alkyl; X = OR1, N(R1)2; Y = :O or represents 2 hydrogen radicals] or pharmaceutically acceptable salts and/or esters thereof. Thus, carbamoylation of (Z)-7-[(1R,2S,3R,5S)-2-(hydroxymethyl)-3,5-bis(tetrahydropyran-2-yloxy)cyclopentyl]hept-5-enoic acid Me ester with Bu isocyanate in the presence of DABCO in THF followed by treatment with pyridinium p-toluenesulfonate in MeOH gave (Z)-7-[(1R,2S,3R,5S)-2-[(butylcarbamoyloxy)methyl]-3,5-dihydroxycyclopentyl]hept-5-enoic acid Me ester which was silylated with tert-butyldimethylsilyl chloride in the presence of Et3N and 4-dimethylaminopyridine in CH2Cl2 to give (Z)-7-[(1R,2S,3R,5S)-2-[(butylcarbamoyloxy)methyl]-3-(tert-butyldimethylsilyloxy)-5-hydroxycyclopentyl]hept-5-enoic acid Me ester (II). Oxidation of II with tetrapropylammonium perruthenate, 4-methylmorpholine N-oxide, and 4Å mol. sieves in CH2Cl2 to give (Z)-7-[(1R,2S,3R)-2-[(butylcarbamoyloxy)methyl]-3-(tert-butyldimethylsilyloxy)-5-oxocyclopentyl]hept-5-enoic acid Me ester which was treated with HF-pyridine in MeCN to give (Z)-7-[(1R,2S,3R)-2-[(butylcarbamoyloxy)methyl]-3-hydroxy-5-oxocyclopentyl]hept-5-enoic acid Me ester (III).

AN 2005:220145 CAPLUS

DN 142:297917

TI Preparation of 2-(thiocarbamoyloxy)- and 2-(carbamoyloxy)cyclopentane-1-heptan(en)ic acid compounds for treating ocular hypertension

IN Old, David W.; Burk, Robert M.

PA Allergan, Inc., USA

SO U.S. Pat. Appl. Publ., 12 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005054689	A1	20050310	US 2003-659091	20030909
	AU 2004272524	A1	20050324	AU 2004-272524	20040818
	CA 2537794	AA	20050324	CA 2004-2537794	20040818
	WO 2005026109	A1	20050324	WO 2004-US27001	20040818

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP 1663961 A1 20060607 EP 2004-781645 20040818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRAI US 2003-659091 A 20030909
WO 2004-US27001 W 20040818
OS CASREACT 142:297917; MARPAT 142:297917

=> d his

(FILE 'HOME' ENTERED AT 13:06:48 ON 08 AUG 2006)

FILE 'REGISTRY' ENTERED AT 13:06:55 ON 08 AUG 2006

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 2 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:07:40 ON 08 AUG 2006

L4 1 S L3

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:07:14 ON 08 AUG 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s ((prostaglandin(w)e2) or PGE2) and (ocular(w)hypertension)
'E2' NOT FOUND
The E# entered is not currently defined.

=> s ((prostaglandin(w)'E2') or PGE2) and (ocular(w)hypertension)

1 FILE ADISCTI
13 FILE BIOSIS
1 FILE BIOTECHABS
1 FILE BIOTECHDS
1 FILE BIOTECHNO
27 FILE CAPLUS
3 FILE DDFU
3 FILE DGENE
23 FILES SEARCHED...
4 FILE DRUGU
17 FILE EMBASE
28 FILE IFIPAT
1 FILE IMSRESEARCH
6 FILE JICST-EPLUS
15 FILE MEDLINE
3 FILE PASCAL
1 FILE PHAR

51 FILES SEARCHED...
1 FILE PROMT
5 FILE PROUSDDR
4 FILE SCISEARCH
15 FILE TOXCENTER
39 FILE USPATFULL
4 FILE USPAT2
25 FILE WPIDS
25 FILE WPINDEX
6 FILE DPCI
59 FILE EPFULL

73 FILES SEARCHED...
1 FILE IMSPATENTS
5 FILE INPADOC

79 FILES SEARCHED...
139 FILE PCTFULL

87 FILES SEARCHED...

29 FILES HAVE ONE OR MORE ANSWERS, 92 FILES SEARCHED IN STNINDEX

L1 QUE ((PROSTAGLANDIN(W)'E2') OR PGE2) AND (OCULAR(W)HYPERTENSION)

=> file biosis medline embase uspatfull epfull pctfull		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.05	3.26

FILE 'BIOSIS' ENTERED AT 14:10:03 ON 08 AUG 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 14:10:03 ON 08 AUG 2006

FILE 'EMBASE' ENTERED AT 14:10:03 ON 08 AUG 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 14:10:03 ON 08 AUG 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EPFULL' ENTERED AT 14:10:03 ON 08 AUG 2006
COPYRIGHT (C) 2006 European Patent Office / FIZ Karlsruhe

FILE 'PCTFULL' ENTERED AT 14:10:03 ON 08 AUG 2006
COPYRIGHT (C) 2006 Univentio

=> s ((prostaglandin(w)'E2') or PGE2)'and (ocular(w)hypertension)
L2 282 ((PROSTAGLANDIN(W)'E2') OR PGE2) AND (OCULAR(W)HYPERTENSION)

=> s l2 not py>2002
L3 161 L2 NOT PY>2002

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 146 DUP REM L3 (15 DUPLICATES REMOVED)

=> d l4 1-30 ti

L4 ANSWER 1 OF 146 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN DUPLICATE 1
TI Omega-cycloalkyl 17-heteroaryl prostaglandin E2
analogs as EP2-receptor agonists.

L4 ANSWER 2 OF 146 USPATFULL on STN
TI Ophthalmic compositions for treating ocular
hypertension

L4 ANSWER 3 OF 146 USPATFULL on STN
TI Combinations of prostaglandins and brimonidine or derivatives thereof

L4 ANSWER 4 OF 146 USPATFULL on STN
TI Prostaglandin agonists and their use to treat bone disorders

L4 ANSWER 5 OF 146 USPATFULL on STN
TI Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl
derivatives as therapeutic agents

L4 ANSWER 6 OF 146 USPATFULL on STN
TI Upregulation of endogenous prostaglandins to lower intraocular pressure

L4 ANSWER 7 OF 146 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN
TIEN SUSTAINED RELEASE PREPARATIONS OF PHYSIOLOGICALLY ACTIVE COMPOUND HARDLY
SOLUBLE IN WATER AND PRODUCTION PROCESS AND USE OF THE SAME.
TIFR PREPARATIONS A LIBERATION LENTE CONTENANT UN COMPOSE PHYSIOLOGIQUEMENT
ACTIF PEU SOLUBLE DANS L'EAU ET METHODE DE PRODUCTION ET D'UTILISATION
DESDITES PREPARATIONS.
TIDE ZUSAMMENSETZUNGEN ZUR VERZOEGERTEN ABGABE VON PHYSIOLOGISCH AKTIVEN
VERBINDUNGEN DIE KAUM WASSERLOESLICH SIND, VERFAHREN ZU DEREN
HERSTELLUNG UND DEREN VERWENDUNG.

L4 ANSWER 8 OF 146 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN
TIEN CYCLOPENTAN(EN)OIC ACID, 2-ALKENYL DERIVATIVES AS THERAPEUTIC AGENTS IN
THE TREATMENT OF OCULAR HYPERTENSION.
TIFR DERIVES D'ACIDE CYCLOPENTAN(EN)O QUE, 2-ALCENYLE UTILISES EN TANT
QU'AGENTS THERAPEUTIQUES DANS LE TRAITEMENT DE L'HYPERTENSION OCULAIRE.
TIDE CYCLOPENTAN(EN)SAEURE-2-ALKENYL-DERIVATE ALS THERAPEUTIKA IN DER
BEHANDLUNG DER OKULAEAREN HYPERTONIE.

L4 ANSWER 9 OF 146 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN

TIEN CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS.
 TIFR DERIVES 2-HETEROARYLALCENYL DE L'ACIDE CYCLOPENTANE HEPTAN(EN)OIQUE UTILISES COMME AGENTS THERAPEUTIQUES.
 TIDE CYCLOPENTANE HEPTAN(ENE)SAeURE, 2-HETEROARYLALKENYLDERIVATE ALS THERAPEUTISCHES MITTEL.

L4 ANSWER 10 OF 146 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN
 TIEN CYCLOPENTANE HEPTANOIC OR HEPTENOIC ACID, 2-ARYLALKYL OR ARYLALKENYL AND DERIVATIVES AS THERAPEUTIC AGENTS.
 TIFR ACIDE HEPTANOIQUE OU HEPTENOIQUE CYCLOPENTANIQUE, 2-ARYLALKYLE OU ARYLALCENYLE ET DERIVES DE CES DERNIERS UTILISES COMME AGENTS THERAPEUTIQUES.
 TIDE 2-AZYLALKYL-ODER ARYLALENYL-CYCLOPENTANHEPTAN-UND HEPTENSAeUREN, DERIVATE UND THERAPEUTISCHE ANWENDUNG.

L4 ANSWER 11 OF 146 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN
 TIEN NOVEL 7-(5-SUBSTITUTED CYCLOPENTYL) AND (5-SUBSTITUTED CYCLOPENTENYL) HEPTYL ALCOHOLS, HEPTYLAMINES AND HEPTANOIC ACID AMINES, AND METHOD OF LOWERING INTRAOCULAR PRESSURE IN THE EYE OF A MAMMAL BY ADMINISTRATION OF THESE NOVEL COMPOUNDS.
 TIFR NOUVEAUX ALCOOLS DE 7-(CYCLOPENTYL SUBSTITUE EN POSITION 5) ET (CYCLOPENTENYL SUBSTITUE EN POSITION 5)-HEPTYLE, HEPTYLAMINES ET AMIDES D'ACIDE HEPTANOIQUE, ET PROCEDE DE REDUCTION DE LA PRESSION INTRA-OCULAIRE CHEZ UN MAMMIFERE PAR L'ADMINISTRATION DE CES NOUVEAUX COMPOSES.
 TIDE 7-(5-SUBSTITUIERTES ZYKLOPENTYL) UND (5-SUBSTITUIERTES ZYKLOPENTYL) HEPTYL-ALKOHOL, HEPTYLAMINE UND HEPTAN-SAeURE-AMIDE UND DAS VERFAHREN ZUR SENKUNG DES AUGENINNENDRUCKS BEI SAeUGETIEREN DURCH ANWENDUNG DIESER NEUEN VERBINDUNGEN.

L4 ANSWER 12 OF 146 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN
 TIEN Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension.
 TIFR Derives de prostaglandine pour traitement du glaucome ou hypertension oculaire.
 TIDE Prostaglandinderivate zur Behandlung des gruenen Stars oder einer okularen Hypertension.

L4 ANSWER 13 OF 146 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN 3, 7 OR 3 AND 7 THIA OR OXA PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE
 TIFR DERIVES D'ACIDE 3, 7 OU 3 ET 7 THIA OU OXA PROSTANOIQUE UTILISES COMME AGENTS POUR REDUIRE LA PRESSION INTRAOCULAIRE

L4 ANSWER 14 OF 146 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN CYCLOPENTANE HEPTAN (ENE) ACYL SULFONAMIDE, 2-ALKYL OR 2-ARYLALKYL, OR 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS
 TIFR DERIVES DE CYCLOPENTANE HEPTAN(ENE) ACYLE SULFONAMIDE, 2-ALKYLE OU 2-ARYLALKYLE, OU 2-HETEROARYLALCENYLE EN TANT QU'AGENTS THERAPEUTIQUES

L4 ANSWER 15 OF 146 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN HYPOTENSIVE LIPID AND TIMOLOL COMPOSITIONS AND METHODS OF USING SAME
 TIFR COMPOSITIONS A BASE DE TIMOLOL ET DE LIPIDE HYPOTENSEUR ET METHODES D'UTILISATION ASSOCIEES

L4 ANSWER 16 OF 146 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE
 TIFR DERIVES D'ACIDE PROTANOIQUE UTILISES EN TANT QU'AGENTS D'ABAISSEMENT DE LA PRESSION INTRAOCULAIRE

L4 ANSWER 17 OF 146 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN METHOD FOR TREATING OCULAR HYPERTENSION AND GLAUCOMA
 TIFR METHODE DE TRAITEMENT DE L'HYPERTENSION OCULAIRE ET DU GLAUCOME

L4 ANSWER 18 OF 146 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN 3, 7 OR 3 AND 7 THIA OR OXA PROSTANOIC ACID DERIVATIVES AS AGENTS FOR
 LOWERING INTRAOCULAR PRESSURE
 TIFR DERIVES D'ACIDES PROSTANOIQUES 3, 7 OU 3 ET 7 THIA OU OXA UTILISES COMME
 AGENTS PERMETTANT DE BAISSER LA TENSION INTRAOCULAIRE

L4 ANSWER 19 OF 146 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN ENZYMES
 TIFR ENZYMES

L4 ANSWER 20 OF 146 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN ENZYMES
 TIFR ENZYMES

L4 ANSWER 21 OF 146 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN COMBINATION THERAPY FOR LOWERING AND CONTROLLING INTRAOCULAR PRESSURE
 TIFR THERAPIE COMBINEE ABAISSANT ET REGULANT LA TENSION INTRAOCULAIRE

L4 ANSWER 22 OF 146 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN 2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY DERIVATIVES OF
 CYCLOPENTYL-HEPTAN(ENE)OIC ACID AS THERAPEUTIC AGENTS
 TIFR DERIVES 2-THIOCARBAMOYLOXY ET 2-CARBAMOYLOXY D'ACIDE
 CYCLOPENTYL-HEPTAN(ENE)OIQUE EN TANT QU'AGENTS THERAPEUTIQUES

L4 ANSWER 23 OF 146 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS
 TIFR DERIVES DE CYCLOPENTANE UTILISES COMME AGENTS THERAPEUTIQUES

L4 ANSWER 24 OF 146 USPATFULL on STN
 TI Combinations of prostaglandins and brimonidine or derivatives thereof

L4 ANSWER 25 OF 146 USPATFULL on STN
 TI Method of enhancing hair growth

L4 ANSWER 26 OF 146 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN
 TIEN METHOD FOR EFFECTING VASODILATION WITH (1,5-INTER)ARYL PROSTAGLANDIN
 DERIVATIVES.
 TIFR METHODE DE VASODILATATION A L'AIDE DE DERIVES DE (1,5-INTER)ARYL-
 PROSTAGLANDINE.
 TIDE METHODE ZUR GEFAESSERWEITERUNG MIT (1,5-INTER)ARYLPROSTAGLANDINDERIVATEN

L4 ANSWER 27 OF 146 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN
 TIEN CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLAKENYL DERIVATIVES AS
 THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR
 HYPERTENSION.
 TIFR UTILISATION DE DERIVES D'ACIDE CYCLOPENTANE HEPTAN(ENE)OIQUE,
 2-HETEROARYLALKENYLE EN TANT QU'AGENTS THERAPEUTIQUES POUR LE TRAITEMENT
 DE L'HYPERTENSION OCULAIRE.
 TIDE 2-HETEROARYLALKENYLDERIVATE DER CYCLOPENTANO-HEPTAN(HEPTAEN)SAEURE ALS
 THERAPEUTISCHES MITTEL ZUR BEHANDLUNG DES ERHOECHTEN AUGENINNENDRUCKES.

L4 ANSWER 28 OF 146 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN
 TIEN EP2-RECEPTOR AGONISTS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE.
 TIFR AGONISTES DE RECEPTEUR EP2 UTILISES COMME AGENTS FAISANT BAISSER LA
 TENSION INTRAOCULAIRE.
 TIDE EP2-REZEPTORAGONISTEN ALS MITTEL ZUR SENKUNG DES AUGENINNENDRUCKS.

L4 ANSWER 29 OF 146 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN
 TIEN USE OF 9-DEOXY PROSTAGLANDIN DERIVATIVES TO TREAT GLAUCOMA.
 TIFR UTILISATION DE DERIVES DE LA 9-DESOXY PROSTAGLANDINE POUR TRAITER LE
 GLAUCOME.
 TIDE VERWENDUNG VON 9-DEOXYPROSTAGLANDINDERIVATEN ZUR BEHANDLUNG VON GLAUKOM.

L4 ANSWER 30 OF 146 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN

TIEN NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL
 DERIVATIVES AS THERAPEUTIC AGENTS.
 TIFR DERIVES NON-ACIDES DE 2-CYCLOALKYLE OU D'ARYLALKYLE D'ACIDE HEPTANOIQUE
 DE CYCLOPENTANE EN TANT QU'AGENTS THERAPEUTIQUES.
 TIDE 2-ZYKLOALKYL-ODER ARYLALKYL-DERIVATE VON NICHT-SAEURE,
 ZYKLOPENTANE-HEPTANOIC-SAEURE.

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

7.49

10.75

FILE 'REGISTRY' ENTERED AT 14:11:39 ON 08 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 7 AUG 2006 HIGHEST RN 899508-12-4

DICTIONARY FILE UPDATES: 7 AUG 2006 HIGHEST RN 899508-12-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s PGE2/cn

L5 1 PGE2/CN

=> d 15

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 363-24-6 REGISTRY

ED Entered STN: 16 Nov 1984

CN Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-,
 (5Z,11α,13E,15S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Heptenoic acid, 7-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-
 (8CI)

CN 5-Heptenoic acid, 7-[3α-hydroxy-2-(3-hydroxy-1-octenyl)-5-
 oxocyclopentyl]- (7CI)

OTHER NAMES:

CN (-)-Prostaglandin E2

CN (15S)-Prostaglandin E2

CN 11α,15α-Dihydroxy-9-ketoprost-5,13-dienoic acid

CN 11α,15α-Dihydroxy-9-oxo-5-cis,13-trans-prostadienoic acid

CN Cervidil

CN Cerviprime

CN Cerviprost

CN Dinoprostone


CN Enzaprost E

CN Glandin

CN 1-PGE2

CN 1-Prostaglandin E2
 CN Minprostitin E2
 CN Minprostoin E2
 CN NSC 165560
 CN NSC 196514
 CN PGE2
 CN Prepidil
 CN Primiprost
 CN Propess
 CN Prostaglandin E2
 CN Prostarmon E
 CN Prostenon
 CN Prostenone
 CN Prostin
 CN Prostin (prostaglandin)
 CN Prostin E2
 CN U 12062
 FS STEREOSEARCH
 MF C20 H32 O5
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO,
 CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,
 CSCHEM, CSNB, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,
 IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PHAR, PROMT, PS, RTECS*,
 SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

26746 REFERENCES IN FILE CA (1907 TO DATE)
 128 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 26777 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
7.10	17.85

FILE 'CAPLUS' ENTERED AT 14:11:58 ON 08 AUG 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Aug 2006 VOL 145 ISS 7

FILE LAST UPDATED: 7 Aug 2006 (20060807/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l5 and (ocular(w)hypertension)

26777 L5

16660 OCULAR

80052 HYPERTENSION

797 OCULAR (W) HYPERTENSION

L6 13 L5 AND (OCULAR (W) HYPERTENSION)

=> s l6 not py>2002

4166028 PY>2002

L7 13 L6 NOT PY>2002

=> d l7 1-13 ti

L7 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

TI 14-Aza prostaglandins for the treatment of glaucoma and ocular hypertension

L7 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

TI Cyclobutane prostaglandin analogs as ocular hypotensive agents

L7 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

TI Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma

L7 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

TI Antagonist of platelet-activating factor prevents prostaglandin E2 induced ocular hypertension in rabbits

L7 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

TI Eicosanoids as a new class of ocular hypotensive agents. 1. The apparent therapeutic advantages of derived prostaglandins of the A and B type as compared with primary prostaglandins of the E, F and D type

L7 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

TI Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

TI Effect of β -adrenoblockers on prostaglandin-induced ocular hypertension in rabbits

L7 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

TI Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes

L7 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

TI A comparison of the miotic and inflammatory effects of biologically active polypeptides and prostaglandin E2 on the rabbit eye

L7 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Effect of dipyridamole on prostaglandin-induced ocular hypertension in rabbits

L7 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Consensual ocular hypertensive responses to prostaglandin E2

L7 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Consensual ocular hypertensive response to prostaglandin

L7 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Mechanism of the antagonism of experimentally induced ocular hypertension by polyphlorethin phosphate

=> d 17 3 5 6 8 9 ti abs bib

L7 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
 AB Combinations of ≥ 1 clonidine derivative (Markush included) and ≥ 1 prostaglandin are used to treat glaucoma and ocular hypertension without some of the side effects typically associated with topical administration of prostaglandins (no data).
 AN 1994:418080 CAPLUS
 DN 121:18080
 TI Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
 IN Desantis, Louis, Jr.; Sallee, Verney L.
 PA Alcon Laboratories, Inc., USA
 SO PCT Int. Appl., 19 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9408585	A1	19940428	WO 1993-US9742	19931012
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9453286	A1	19940509	AU 1994-53286	19931012
	AU 674038	B2	19961205		
	EP 664707	A1	19950802	EP 1993-923372	19931012
	EP 664707	B1	19970604		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 153855	E	19970615	AT 1993-923372	19931012
	ES 2105333	T3	19971016	ES 1993-923372	19931012
	JP 3002258	B2	20000124	JP 1994-510215	19931012
	JP 08502485	T2	19960319		
	CA 2146127	C	20000613	CA 1993-2146127	19931012
	US 5480900	A	19960102	US 1995-422570	19950410
	US 5605922	A	19970225	US 1995-571326	19951212
	US 5811443	A	19980922	US 1997-803667	19970221
PRAI	US 1992-960065	A	19921013		
	WO 1993-US9742	W	19931012		
	US 1994-213380	B1	19940314		
	US 1995-422570	A1	19950410		
	US 1995-571326	A1	19951212		
OS	MARPAT 121:18080				

L7 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Eicosanoids as a new class of ocular hypotensive agents. 1. The apparent therapeutic advantages of derived prostaglandins of the A and B type as compared with primary prostaglandins of the E, F and D type
 AB A and B prostaglandins (PGs) which are derived from PGs of the E type by

dehydration and isomerization, have a much greater ocular hypotensive potency than the primary PGs of the E, F, or D type. A single application of 5 µg PGA2 to the cat eye in a 25-µL volume of aqueous vehicle solution yielded a greater and more prolonged ocular hypotensive effect than as much as 100 µg of topically applied PGF2α. As little as 1 µg of PGA2 had an ocular hypotensive effect that was enhanced by ≥3 consecutive daily applications of the same dose. This intraocular pressure reduction, which remained for several days after the last of 10 daily treatments, was not associated with biomicroscopically detectable flare or invasion of the anterior chamber by cells. Although PFG2α and, to a much lesser extent, PGE2 have a miotic effect in cats, PGs of the A and B type did not cause miosis even at doses 50-100-fold greater than the min. dose required to yield ocular hypotension. PGA2 retained its ocular hypotensive potency when stored in an aqueous solution at room temperature for

4 mo.

The conjunctival hyperemia caused by 5 or 10 µg A or B type PGs on rabbit eyes was milder and shorter in duration than that caused by the same doses of PGE2 or PGF2α. Thus, derived PGs, especially PGs of the A type, may have a therapeutic advantage over primary PGs for the treatment of ocular hypertension and glaucoma.

AN 1987:509969 CAPLUS

DN 107:109969

TI Eicosanoids as a new class of ocular hypotensive agents. 1. The apparent therapeutic advantages of derived prostaglandins of the A and B type as compared with primary prostaglandins of the E, F and D type

AU Bito, Laszlo Z.; Baroody, Roger A.; Miranda, Olivia C.

CS Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA

SO Experimental Eye Research (1987), 44(6), 825-37

CODEN: EXERA6; ISSN: 0014-4835

DT Journal

LA English

L7 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

TI Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma

AB Ocular hypertension and glaucoma can be effectively controlled through topical application of an effective amount of an eicosanoid or an eicosanoid derivative to the surface of an afflicted eye. PGE2 [363-24-6] and PGF2α [551-11-1], and derivatives thereof, were effective in quantities <100 µg/eye. For example, the relative intraocular hypotensive potencies of prostaglandins that yielded intraocular pressure reduction of ≥5 mm Hg 6 h after topical application to cats were: PGF2α Me ester [33854-16-9] » PGE2 > PGF2α tromethamine salt [38562-01-5] > PGF2α.

AN 1984:115579 CAPLUS

DN 100:115579

TI Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma

IN Bito, Laszlo Z.

PA Columbia University, USA

SO Eur. Pat. Appl., 36 pp.

CODEN: EPXXDW

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 93380	A2	19831109	EP 1983-104083	19830426
	EP 93380	A3	19840328		
	EP 93380	B1	19870114		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4599353	A	19860708	US 1982-374165	19820503
	AU 560189	B2	19870402	AU 1983-13916	19830426
	JP 59001418	A2	19840106	JP 1983-76053	19830428
	JP 04068288	B4	19921102		

CA 1208560	A1	19860729	CA 1983-427097	19830429
DK 8301950	A	19831104	DK 1983-1950	19830502
PRAI US 1982-374165	A	19820503		
OS MARPAT 100:115579				


L7 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes
 GI



AB Intraocular pressure (IOP) reduction was maintained in cats for up to 9 mo by topical application of PGE2 (I) [363-24-6] at 12-, 24-, or 48-h intervals. The IOP reduction was jeopardized seriously only when I was applied every other day for several days or when, on a few occasions, 3 days were allowed to elapse between I applications. Ocular hypotension was also maintained during the course of topical treatment of rhesus monkey eyes with PGF2 α [551-11-1]. Short periods of pupillary constriction followed the application of each dose of PGF2 α to cat eyes, but the miotic response of rhesus monkeys to PGF2 α and cats to I was negligible. Other apparent side effects were noted, but none of these were severe or progressive. Thus, tachyphylaxis, or tolerance, is not expected to present an obstacle to the development of eicosanoids and(or) their derivs. as therapeutic agents for the long-term treatment of ocular hypertension and chronic glaucoma.

AN 1983:417207 CAPLUS
 DN 99:17207
 TI Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes
 AU Bito, L. Z.; Draga, A.; Blanco, J.; Camras, C. B.
 CS Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA
 SO Investigative Ophthalmology & Visual Science (1983), 24(3), 312-19
 CODEN: IOVSDA; ISSN: 0146-0404
 DT Journal
 LA English

L7 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
 TI A comparison of the miotic and inflammatory effects of biologically active polypeptides and prostaglandin E2 on the rabbit eye
 GI



AB The ocular effects of some biol. active peptides were studied and compared to those of PGE2 (I) [363-24-6] to determine whether the responses of the eye to trauma, characterized by increased intraocular pressure

(IOP), the development of anterior chamber flare, and partial miosis, might be mediated by such peptides. At 1-2 h after intravitreal injection of 10 µg of I into rabbit eyes, ocular hypertension, flare, and iridial hyperemia, but only minimal miosis were observed. Maximum miosis developed within 2-3 h after intravitreal injection of 1.0-100 µg of substance P (SP) [33507-63-0], SP-octapeptide (SP-8) [53749-60-3], coherin [9044-70-6], or eledoisin-related peptide (EDR) [2990-43-4], whereas 10-100 µg of VIP [37221-79-7], somatostatin [51110-01-1], or bradykinin (BK) [58-82-2] yielded only submaximal miosis and angiotensin II [11128-99-7], α-MSH [37213-49-3], and poly-DL-alanine [25281-63-4] had little or no miotic effect. None of these peptides caused iridial hyperemia or a cellular invasion of the anterior chamber and only high doses (100 µg) of VIP or BK caused significant increases in the protein concentration of the aqueous humor.

Miotic

doses of SP, SP-8, or EDR caused a significant increase in IOP in some, but not all, expts. Thus, I can be regarded as a mediator of the ocular irritative response although it may not account for the miosis that is associated with chemical or surgical trauma. In contrast, some polypeptides, particularly SP, SP-8, and EDR are strong miotics and, at least under some circumstances, can act as effective ocular hypertensives, but these peptides do not reproduce any other signs of ocular irritation or inflammation. Apparently, none of the peptides studied could, by itself, be the sole mediator of the initial ocular irritative response although some of them may account for the miosis and contribute to the ocular hypertension associated with this response. A combination of some of these peptides together with I and(or) other prostaglandins may account for all aspects of the ocular irritative response and for most aspects of the ocular inflammatory response.

AN 1982:211568 CAPLUS

DN 96:211568

TI A comparison of the miotic and inflammatory effects of biologically active polypeptides and prostaglandin E2 on the rabbit eye

AU Bito, L. Z.; Nichols, R. R.; Baroody, R. A.

CS Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA

SO Experimental Eye Research (1982), 34(3), 325-37

CODEN: EXERA6; ISSN: 0014-4835

DT Journal

LA English

=> d his

(FILE 'HOME' ENTERED AT 14:06:58 ON 08 AUG 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:07:14 ON 08 AUG 2006
SEA ((PROSTAGLANDIN(W)'E2') OR PGE2) AND (OCULAR(W)HYPERTENSION

```

-----
1  FILE ADISCTI
13  FILE BIOSIS
1  FILE BIOTECHABS
1  FILE BIOTECHDS
1  FILE BIOTECHNO
27  FILE CAPLUS
3  FILE DDFU
3  FILE DGENE
4  FILE DRUGU
17  FILE EMBASE
28  FILE IFIPAT
1  FILE IMSRESEARCH
6  FILE JICST-EPLUS
15  FILE MEDLINE

```

3 FILE PASCAL
 1 FILE PHAR
 1 FILE PROMT
 5 FILE PROUSDDR
 4 FILE SCISEARCH
 15 FILE TOXCENTER
 39 FILE USPATFULL
 4 FILE USPAT2
 25 FILE WPIDS
 25 FILE WPINDEX
 6 FILE DPCI
 59 FILE EPFULL
 1 FILE IMSPATENTS
 5 FILE INPADOC
 139 FILE PCTFULL

L1 QUE ((PROSTAGLANDIN(W)'E2') OR PGE2) AND (OCULAR(W)HYPERTENSION

FILE 'BIOSIS, MEDLINE, EMBASE, USPATFULL, EPFULL, PCTFULL' ENTERED AT
 14:10:03 ON 08 AUG 2006

L2 282 S ((PROSTAGLANDIN(W)'E2') OR PGE2) AND (OCULAR(W)HYPERTENSION)
 L3 161 S L2 NOT PY>2002
 L4 146 DUP REM L3 (15 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 14:11:39 ON 08 AUG 2006

L5 1 S PGE2/CN

FILE 'CAPLUS' ENTERED AT 14:11:58 ON 08 AUG 2006

L6 13 S L5 AND (OCULAR(W)HYPERTENSION)
 L7 13 S L6 NOT PY>2002

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
25.22	43.07

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-3.75	-3.75

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 14:13:59 ON 08 AUG 2006